Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Mol Cancer Ther. 2018 Oct 10;18(1):162–172. doi: 10.1158/1535-7163.MCT-17-1050

Figure 1.

Figure 1.

PRKRA expression and function in MOC. A, Results from the kinome-based siRNA library screen. Left, heat map with genes according to the ratio of MOC samples given siRNA to the samples given siRNA plus oxaliplatin. Right, cell viability assay for RMUG-L-ip1 cells given combination therapy with oxaliplatin and siPRKRA. The experiment was performed 72 hours after treatment. B, Colony formation assay for RMUG-S-ip1 cells given combination therapy with oxaliplatin and siPRKRA or control siRNA. C, Western blot analysis of PACT expression in non-transformed epithelial ovarian cells (HIO-180) and in ovarian cancer cell lines. D, Cell viability assay for A2780 cells treated with oxaliplatin. The cells were transfected with either a control vector or the pcDNA-PACT vector. The experiment was performed 72 hours after treatment. E, Cell viability assay for A2780-CP20 cells given combination therapy with oxaliplatin and siPRKRA. The experiment was performed 72 hours after treatment. The data are presented as means ± standard error of the mean for at least three experimental groups. **P < 0.01; ***P < 0.001; ****P < 0.0001 (Student t-test).